Cassava Sciences Valuation
Is SAVA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SAVA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SAVA *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SAVA *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SAVA *?
Key metric: As SAVA * is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is SAVA *'s PB Ratio? | |
|---|---|
| PB Ratio | 1.1x |
| Book | US$166.64m |
| Market Cap | US$206.63m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -0.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does SAVA *'s PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.2x | ||
LAB B Genomma Lab Internacional. de | 2.2x | 19.8% | Mex$24.0b |
002693 Hainan Shuangcheng Pharmaceuticals | 23.4x | n/a | CN¥10.2b |
4887 Sawai Group Holdings | 1.2x | 2.7% | JP¥246.0b |
4506 Sumitomo Pharma | 2.1x | 88.7% | JP¥238.8b |
SAVA * Cassava Sciences | 1.1x | 58.3% | Mex$206.6m |
Price-To-Book vs Peers: SAVA * is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (7.2x).
Price to Book Ratio vs Industry
How does SAVA *'s PB Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 56 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 56 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: SAVA * is good value based on its Price-To-Book Ratio (1.1x) compared to the Global Pharmaceuticals industry average (2x).
Price to Book Ratio vs Fair Ratio
What is SAVA *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate SAVA *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Organon
US$3.9b
Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
OGN *
US$343.00
7D
0%
1Y
80.5%